Here, we investigated the predictive value of ESPL1, PTTG1 and PTTG1IP gene expression for achievement of MMR under TKI first-line therapy within 12 months in newly diagnosed CML patients (n = 97). The gene discussed is PTTG1IP; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.